EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The study of the domestic market of antiviral drugs for the pharmacotherapy of complicated influenza in Ukraine

O. M. Semenov

News of Pharmacy · 31.03.2026 · 111 (1) · 89-94

DOI: 10.24959/nphj.26.207 ↗

Kurz gefasst

Fachartikel in der Zeitschrift News of Pharmacy, online erschienen am 31.03.2026. Verfasst von O. M. Semenov. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To study the domestic market of antiviral drugs – neuraminidase inhibitors, which are recommended by the clinical treatment protocols for the pharmacotherapy of patients with complicated forms of influenza; to determine their cost aspects and accessibility for the patient. Materials and methods. The normative and legislative acts and sources of scientific literature on the pharmaceutical component of the treatment of complicated forms of influenza using antiviral drugs, neuraminidase inhibitors (ATC code J05A H), in Ukraine were reviewed. The pharmaceutical market of Ukraine was analyzed in terms of the availability and accessibility of this group of drugs to the population.

Results

Among acute respiratory viral infections, influenza is a key disease among the population in terms of the number of reported cases, severe complications and disability. Severe forms of influenza require inpatient treatment of patients using antiviral drugs. According to the clinical treatment protocol and the WHO recommendations, it is recommended to use neuraminidase inhibitors (J05A H), including Oseltamivir, Zanamivir, Laninavir and Piramivir with the activity against various strains of the influenza virus, for the pharmacotherapy of complicated forms of influenza. Neuraminidase inhibitors are represented in the domestic pharmaceutical market of Ukraine by 15 trade names of foreign manufacturers, which indicates complete import dependence and requires the development and introduction of domestic antiviral drugs into production.

Conclusions

Severe forms of influenza can lead to significant complications of the patient’s disease, and, therefore, the use of neuraminidase inhibitors should prevent the occurrence of severe pathological changes in the patient’s body. The most affordable drug for the patient is Oseltamivir, 75 mg, No. 10 manufactured by Strides India, the course of treatment for which in 2026 will be 5 % of the patient’s minimum wage.

Zitieren

APA

Semenov, O. M. (2026). The study of the domestic market of antiviral drugs for the pharmacotherapy of complicated influenza in Ukraine. News of Pharmacy, 111(1), 89-94. https://doi.org/10.24959/nphj.26.207

Vancouver

Semenov OM. The study of the domestic market of antiviral drugs for the pharmacotherapy of complicated influenza in Ukraine. News of Pharmacy. 2026;111(1):89-94. doi:10.24959/nphj.26.207

BibTeX
@article{Semenov2026,
  author = {Semenov, O. M.},
  title = {The study of the domestic market of antiviral drugs for the pharmacotherapy of complicated influenza in Ukraine},
  journal = {News of Pharmacy},
  year = {2026},
  volume = {111},
  number = {1},
  pages = {89--94},
  doi = {10.24959/nphj.26.207}
}
Kostenlos starten →